Literature DB >> 2110878

Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

R Ansorg1, K D Müller, J Wiora.   

Abstract

Using a broth microtiter dilution method, the minimum inhibitory (MIC) and minimum bactericidal concentrations (MBC) of so-called antipseudomonal antibiotics were determined against 79 Pseudomonas aeruginosa isolates from cystic fibrosis patients. On the basis of the MIC values and using DIN breakpoints, the percentual susceptibilities led to the following rank order: imipenem (91%), ciprofloxacin (90%), tobramycin (87%), amikacin (87%), ceftazidime (82%), cefsulodin (76%), piperacillin (71%), azlocillin (62%), followed by gentamicin, ceftriaxone, mezlocillin, netilmicin, and cefotaxime (less than 50%). However, evaluating MBC values according to DIN breakpoints, only ciprofloxacin (82%), tobramycin (77%), amikacin (58%), and imipenem (57%) showed a pronounced antipseudomonal effectiveness. The data indicate that MBC determinations are necessary to evaluate the antibiotic susceptibility of P. aeruginosa rather than MIC determinations, at least in patients with impaired defence mechanisms which require bactericidal therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110878     DOI: 10.1159/000238770

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  5 in total

1.  Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  R M Shawar; D L MacLeod; R L Garber; J L Burns; J R Stapp; C R Clausen; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Innovation in multifunctional bioabsorbable osteoconductive drug-releasing hard tissue fixation devices.

Authors:  N Ashammakhi; M Veiranto; E Suokas; J Tiainen; S-M Niemelä; P Törmälä
Journal:  J Mater Sci Mater Med       Date:  2006-12       Impact factor: 3.896

3.  Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.

Authors:  M J Montgomery; P M Beringer; A Aminimanizani; S G Louie; B J Shapiro; R Jelliffe; M A Gill
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

4.  In vitro mechanical and drug release properties of bioabsorbable ciprofloxacin containing and neat self-reinforced P(L/DL)LA 70/30 fixation screws.

Authors:  M Veiranto; P Törmälä; E Suokas
Journal:  J Mater Sci Mater Med       Date:  2002-12       Impact factor: 3.896

Review 5.  Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

Authors:  Susan M Cheer; John Waugh; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.